A novel fusion of TPR and ALK in lung adenocarcinoma

Journal of Thoracic Oncology

Volumn 9, Issue 4, 2014, Pages 563-566

  Choi, Yoon La ^a,b   Lira, Maruja E ^c   Hong, Mineui ^a   Kim, Ryong Nam ^d   Choi, So Jung ^a   Song, Ji Young ^b   Pandy, Kinnari ^c   Mann, Derrick L ^e   Stahl, Joshua A ^e   Peckham, Heather E ^e   Zheng, Zongli ^f,g   Han, Joungho ^b   Mao, Mao ^c   Kim, Jhingook ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c PFIZER INC   (United States)

^d Seoul National University   (South Korea)

^e ArcherDX Inc   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ALK; Lung cancer; TPR; Translocation

Indexed keywords

ALK ANTIBODY; AMINO ACID; CISPLATIN; COMPLEMENTARY DNA; ENZYME ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; NAVELBINE; TRANSLOCATED PROMOTER REGION ANAPLASTIC LYMPHOMA KINASE FUSION PROTEIN; UNCLASSIFIED DRUG; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; NUCLEOPORIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; TPR PROTEIN, HUMAN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; ALK GENE; ARTICLE; CANCER ADJUVANT THERAPY; CASE REPORT; CHROMOSOME 1; CHROMOSOME 2; CHROMOSOME Q BAND; CHROMOSOME TRANSLOCATION 1; COUGHING; DISEASE DURATION; DNA SEQUENCE; EGFR GENE; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FUSION GENE; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; JUXTAMEMBRANE; KOREAN (PEOPLE); LOBECTOMY; LUNG ADENOCARCINOMA; LUNG TUMOR; MALE; MEDICAL HISTORY; MEMBRANE; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; SMOKING; TPR ALK FUSION GENE; TPR GENE; TREATMENT OUTCOME; TUBERCULOSIS; TUMOR INVASION; ADENOCARCINOMA; GENE REARRANGEMENT; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EXONS; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PORE COMPLEX PROTEINS; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 84922480617     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000093     Document Type: Article

References (15)

1. Lira ME, Kim TM, Huang D, et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn 2013; 15: 51-61.
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
3. Bangs P, Burke B, Powers C, et al. Functional analysis of Tpr: identification of nuclear pore complex association and nuclear localization domains and a role in mRNA export. J Cell Biol 1998; 143: 1801-1812.
4. Albers K, Fuchs E. The molecular biology of intermediate filament proteins. Int Rev Cytol 1992; 134: 243-279.
5. Coyle JH, Bor YC, Rekosh D, et al. The Tpr protein regulates export of mRNAs with retained introns that traffic through the Nxf1 pathway. RNA 2011; 17: 1344-1356.
6. Bangs PL, Sparks CA, Odgren PR, Fey EG. Product of the oncogene-activating gene Tpr is a phosphorylated protein of the nuclear pore complex. J Cell Biochem 1996; 61: 48-60.
7. Gonzatti-Haces M, Seth A, Park M, et al. Characterization of the TPRMET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci U S A 1988; 85: 21-25.
8. Soman NR, Correa P, Ruiz BA, Wogan GN. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A 1991; 88: 4892-4896.
9. Greco A, Pierotti MA, Bongarzone I, et al. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 1992; 7: 237-242.
10. Russell JP, Powell DJ, Cunnane M, et al. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene 2000; 19: 5729-5735.
11. Li F, Zhai YP, Tang YM, et al. Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2012; 51: 890-897.
12. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002; 107: 101-107.
13. Mason DY, Pulford KA, Bischof D, et al. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res 1998; 58: 1057-1062.
14. Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 2002; 20: 3691-3702.
15. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002; 62: 1559-1566.